02080nas a2200505   4500000000100000008004100001260001300042653001500055653001000070653002100080653001000101653001900111653002500130653002600155653002100181653001100202653002200213653001100235653001400246653002300260653001200283653000900295653001600304653002200320653003900342653003000381653003200411653002400443653002000467653003000487653002100517100001300538700001600551700001800567700001700585700001700602700001300619245011900632856005000751300001000801490000700811050001500818520072700833022001401560       2003                            d  c2003 Mar10aAdolescent10aAdult10aAge Distribution10aChild10aCohort Studies10aConfidence Intervals10aDisability Evaluation10aElectromyography10aFemale10aFollow-Up Studies10aHumans10aIncidence10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aNeural Conduction10aPeripheral Nervous System Diseases10aPredictive Value of Tests10aProportional Hazards Models10aProspective Studies10aRisk Assessment10aSeverity of Illness Index10aSex Distribution1 aCroft RP1 aNicholls PG1 aSteyerberg EW1 aRichardus JH1 aWithington S1 aSmith WC00aA clinical prediction rule for nerve function impairment in leprosy patients-revisited after 5 years of follow-up.  uhttps://leprosyreview.org/article/74/1/03-541  a35-410 v74  aCROFT 20033 a<p>Nerve function impairment (NFI) commonly occurs during or after chemotherapy in leprosy. We previously described a clinical prediction rule to estimate the risk of NFI occurring within 2 years of diagnosis, based on 2510 patients who are followed up in the Bangladesh Acute Nerve Damage Study (BANDS). This prediction rule assigns new leprosy patients to one of three risk groups based on leprosy group and the presence or absence of NFI at registration. Updated data with up to 5 years of follow-up showed that 95% of all NFI occurred within 2 years. This study confirms the validity of the rule and supports the conclusion that there is little value for the detection of NFI in extending follow-up beyond 2 years.</p>  a0305-7518